Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
The average for 2022 based on 135 countries was 1.66 percent. The highest value was in Swaziland: 25.9 percent and the lowest value was in Afghanistan: 0.1 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.
Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, Lesotho, and South Africa. In 2023, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased in recent years. However, despite being available worldwide, not all adults have access to antiretroviral drugs. Europe and North America have the highest rates of antiretroviral use among people living with HIV. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.
The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;
As of 2023, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.7 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.4 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by Lesotho and South Africa. However, South Africa had the highest total number of new HIV infections in 2023, with around 150,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the fourth leading cause of death in Africa, accounting for around 5.6 percent of all deaths. In 2023, South Africa and Nigeria were the countries with the highest number of AIDS-related deaths worldwide with 50,000 and 45,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years and now up to 95 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 77 percent of people who are HIV positive in South Africa receiving ART, and only 31 percent in the Congo.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, male (% ages 15-24) in World was reported at 0.2 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. World - Prevalence of HIV, male (% ages 15-24) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.130 Ratio in 2020. This records an increase from the previous number of 0.120 Ratio for 2019. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.020 Ratio from Dec 1990 (Median) to 2020, with 31 observations. The data reached an all-time high of 0.130 Ratio in 2020 and a record low of 0.010 Ratio in 2004. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Arab Emirates – Table AE.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Montenegro ME: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.100 % in 2016. This stayed constant from the previous number of 0.100 % for 2015. Montenegro ME: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.100 % from Dec 1990 (Median) to 2016, with 27 observations. The data reached an all-time high of 0.100 % in 2016 and a record low of 0.100 % in 2016. Montenegro ME: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Montenegro – Table ME.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Finland was reported at 0.1 % in 2018, according to the World Bank collection of development indicators, compiled from officially recognized sources. Finland - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on June of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Children orphaned by HIV/AIDS in World was reported at 13900000 in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. World - Children orphaned by HIV/AIDS - actual values, historical data, forecasts and projections were sourced from the World Bank on June of 2025.
Attribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
Global HIV-AIDS Mortality by Country, 2023 Discover more data with ReportLinker!
CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
Every year, UNAIDS releases updated estimates of the number of people living with HIV and AIDS and the mortality impact of the epidemic, while WHO releases data on the number of people on treatment and the number needing treatment. This dataset, from CGD senior fellow Mead Over and Owen McCarthy, is a compilation of selected variables from these published sources as well as from the World Bank Development Indicators and the International Monetary Fund’s estimates of economic quantities such as Gross Domestic Product and central government health expenditures. The data are in the format developed by the Stata statistical software corporation and are intended for use with the AIDSCost package for the purpose of projecting the future budgetary cost of scaling up AIDS treatment. Instructions on how to download, access, and use the AIDSCost package are included in the users' manual. The authors encourage comments on their blog or as an e-mail to them, which will be considered for posting. (CGD’s HIV/AIDS Monitor Initiative provides access to data on past AIDS funding PEPFAR, the World Bank and the Global Fund.)
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
According to Cognitive Market Research, the global HIV drugs market size will be USD 35425.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.80% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 10627.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
The multi-class combination drugs held the highest HIV drugs market revenue share in 2024.
Market Dynamics of HIV drugs Market
Key Drivers for HIV drugs Market
Rising number of HIV-positive individuals to Increase the Demand Globally
The HIV drugs market has experienced growth due to rising number of HIV-positive individuals. As global HIV prevalence increases due to factors like higher transmission rates and improved diagnostic capabilities, demand for effective antiretroviral therapies (ART) surges. This growing patient base necessitates the continuous development and supply of innovative drugs to manage HIV effectively, reduce viral loads, and improve quality of life. Increased awareness and testing also contribute to higher diagnosed cases, further expanding the market for HIV treatments and driving pharmaceutical companies to invest in research and development.
Innovations in HIV diagnostic tools to Propel Market Growth
The HIV drugs market has witnessed steady growth, driven by innovations in HIV diagnostic tools. Advances include rapid, point-of-care tests that deliver results within minutes, improving patient access and reducing diagnostic delays. Integrated technologies, such as multiplex assays, detect multiple markers simultaneously, increasing diagnostic accuracy. Additionally, digital platforms for data management streamline monitoring and personalized treatment plans. These innovations not only improve patient outcomes but also stimulate demand for more effective HIV treatments and management solutions, fostering market growth.
Restraint Factor for the HIV drugs Market
High cost of HIV treatment to Limit the Sales
The high costs of HIV medications constrain the growth of HIV drugs market. It involves expensive medications that can be unaffordable for many patients, especially in low-income regions. The costs are compounded by the need for lifelong treatment, regular monitoring, and potential side effects management, which further burdens healthcare systems and patients. This financial barrier limits access to effective treatment, leading to disparities in care and hindering efforts to control the HIV epidemic globally.
Impact of Covid-19 on the HIV drugs Market
The Covid-19 significantly impacted the market by disrupting supply chains, leading to delays in drug production and distribution, increasing lockdowns and restrictions. Additionally, the focus on COVID-19 diverted resources away from HIV programs, affecting drug availability and patient adherence. However, the pandemic also accelerated the adoption of telemedicine and digital health solutions, which helped maintain patient care continuity. Overall, the pandemic highlighted the need for resilient healthcare systems in managing chronic diseases. Introduction of the HIV drugs Market
HIV drugs are medications used to treat Human Immunodeficiency Virus (HIV) infection. They work by suppressing the virus, preventing its replication, and protecting the immune system. These drugs are typically used in combination as antiretroviral therapy (ART) to reduce viral load, improve patient outcomes, and prevent the progression to AIDS. The rising number of HIV-positive individuals, advancemnets in drug development, increasing government initiatives and funding, increased aw...
This dataset provides estimates for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) spending for 188 countries for 2000 to 2015. Data is taken from the Institute for Health Metrics and Evaluation (IHME) and the Global Health Data Exchange.
https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
The global HIV and AIDS clinical trials market is experiencing robust growth, driven by the increasing prevalence of HIV/AIDS globally, coupled with ongoing efforts to develop more effective treatment regimens and preventative measures. The market's expansion is fueled by advancements in antiretroviral therapies (ARTs), a rise in research and development activities focusing on novel drug delivery systems, and a growing need for long-acting injectables to improve patient adherence. The pharmaceutical and biopharmaceutical sector is a major driver, investing heavily in clinical trials to bring innovative therapies to market, followed by significant contributions from non-profit organizations dedicated to HIV/AIDS research and patient support. While the market shows strong potential, challenges remain, such as the high cost associated with conducting clinical trials, particularly in resource-limited settings, and the complexity involved in conducting trials across diverse populations with varying disease presentations and access to healthcare. The segmentation by clinical trial phases (Phase I-IV) highlights the diverse stages of drug development and research contributing to the overall market. Geographical analysis reveals that North America and Europe currently hold significant market shares, though emerging economies in Asia-Pacific and Africa present substantial growth opportunities due to increasing prevalence rates and rising government initiatives focused on HIV/AIDS control. Further analysis suggests a promising outlook for the market, with continued growth projected throughout the forecast period (2025-2033). The development of new combination therapies, personalized medicine approaches, and strategies targeting viral reservoirs are expected to further fuel market expansion. The success of these efforts hinges on collaborative partnerships between pharmaceutical companies, research institutions, and governmental bodies to overcome logistical hurdles, ensuring equitable access to cutting-edge treatments and diagnostics across different regions of the world. Effective strategies targeting underserved populations and addressing socio-economic barriers to access will be crucial in maximizing the impact of clinical trials and improving global HIV/AIDS outcomes. The focus on long-acting medications and new approaches like gene therapy are poised to reshape the landscape of HIV/AIDS clinical trials in the coming years.
HIV prevalence among population aged 15-49 of Belgium remained constant at 0.2 % over the last 10 years. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data was reported at 0.200 % in 2017. This stayed constant from the previous number of 0.200 % for 2016. Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data is updated yearly, averaging 0.200 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 0.200 % in 2017 and a record low of 0.100 % in 2009. Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Mexico – Table MX.World Bank.WDI: Health Statistics. Prevalence of HIV, male is the percentage of males who are infected with HIV. Youth rates are as a percentage of the relevant age group.; ; UNAIDS estimates.; Weighted average; In many developing countries most new infections occur in young adults, with young women being especially vulnerable.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.010 % in 2016. This stayed constant from the previous number of 0.010 % for 2015. IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.020 % from Dec 1990 (Median) to 2016, with 27 observations. The data reached an all-time high of 0.040 % in 1995 and a record low of 0.010 % in 2016. IT: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Iraq Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.100 % in 2022. This stayed constant from the previous number of 0.100 % for 2021. Iraq Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.100 % from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.100 % in 2022 and a record low of 0.100 % in 2022. Iraq Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Iraq – Table IQ.World Bank.WDI: Social: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.;UNAIDS estimates.;Weighted average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in United States was reported at 0.4 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
The average for 2022 based on 135 countries was 1.66 percent. The highest value was in Swaziland: 25.9 percent and the lowest value was in Afghanistan: 0.1 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.